Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis. 2019

Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
Division of Pediatric Oncology, Blood and Marrow Transplant, Alberta Children's Hospital, Calgary, Alberta, Canada. Electronic address: tony.truong@ahs.ca.

Access to hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) primarily depends on disease-related factors but may be influenced by social and economic determinants. We included all children aged < 15 years with newly diagnosed ALL in Canada between 2001 and 2018 using the Cancer in Young People in Canada national registry. We examined factors potentially associated with the likelihood of receiving HSCT using univariate and multivariable logistic regression models. A total of 3992 patients with newly diagnosed ALL were included. Three hundred twenty-five (8.1%) received an HSCT and formed the transplant cohort. In multivariable analysis factors independently associated with an increased odds of receiving HSCT were male sex (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.05 to 1.93), initial WBC ≥ 50,000 × 109/L (OR, 1.58; 95% CI, 1.09 to 2.28), mixed phenotype acute leukemia relative to B-precursor ALL (OR, 34.32; 95% CI, 16.64 to 70.79), T cell relative to B-precursor ALL (OR, 1.77; 95% CI, 1.07 to 2.91), unfavorable relative to standard cytogenetics (OR, 3.96; 95% CI, 2.56 to 6.12), and relapse before HSCT (OR, 32.77; 95%, 23.89 to 44.96). No association was found between race, neighborhood income quintile or region at diagnosis, and receipt of HSCT. Diagnosis at an HSCT treating center (OR, 1.51; 95% CI, 1.09 to 2.09) and residential distance from the ALL treating center (OR, 1.84 for ≥300 km compared with <100 km; 95% CI, 1.17 to 2.91) were associated with higher odds of receiving HSCT. In a publically funded healthcare system, children with ALL had equitable access to HSCT, which was largely governed by biologic disease-related factors. Patients diagnosed at an HSCT performing center and patients who live farthest away from their treatment center had higher odds of receiving HSCT, although the effect was small, possibly suggesting preferential referral to HSCT for some patients.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
April 2019, Current hematologic malignancy reports,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
January 2024, Annals of hematology,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
July 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
November 2009, Current opinion in hematology,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
September 2001, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
October 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
January 2015, Pediatric blood & cancer,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
June 2004, Leukemia & lymphoma,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
August 2018, Current oncology reports,
Tony H Truong, and Jason D Pole, and Henrique Bittencourt, and Tal Schechter, and Geoff D E Cuvelier, and Kristjan Paulson, and Meera Rayar, and David Mitchell, and Kirk R Schultz, and Debbie O'Shea, and Randy Barber, and Donna Wall, and Lillian Sung
January 2007, Hematology. American Society of Hematology. Education Program,
Copied contents to your clipboard!